Claire England
Investment Partner @ Green Park & Golf Ventures
Austin, United States
Claire England is a seed investor at Green Park & Golf Ventures in Austin focused on Health Care and Wellness. A seasoned investor with executive experience, Claire England is Investment Partner with GPG Ventures, a healthcare venture capital firm with more than 100 portfolio companies nationally. GPG opens venture-ready investing opportunities in the $4.3 trillion U.S. healthcare market to family offices and individuals, who invest in companies directlyalongside the firm's partners. The firm is built on more than 60 years of healthcare, operational, and financial experience with an extensive syndicate investor network and offices in Dallas, Houston, and Austin.In addition to GPG, she's a partner in two Portfolia funds, Food & AgTech and FemTech I, where she made 22 investments, and a partner in an impact investing advisory firm, LOHAS. She’s also a Kauffman Fellow (a global innovation program and network of 882 VCs and LPs) and a member of Private Equity Women Investor Network, or PEWIN. She serves on St. Edward’s University’s Business School Advisory Board, and she received the 2018 Kauffman Fellows Leadership Award.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Claire England invests in
Stages Claire England invests in
Countries Claire England invests in
Investment Focus
Industry
- Health Care 5 (42%)
- Wellness 3 (25%)
- Medical Device 3 (25%)
- Women's 2 (17%)
- Software 2 (17%)
Stage
- Seed 5 (42%)
- Series B 3 (25%)
- Series A 2 (17%)
- Funding Round 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Affineon Health
|
Affineon is the AI inbox that saves provider time. We automatically handle normal and clinically insignificant lab results, and help providers get through abnormal lab results faster. Our AI automatically groups, analyzes, and trends lab results into a smart summary, including possible next steps and a complete patient note. We also route"noise" to staff, reducing the number of messages a physician needs to pay attention to by up to 30%. The result is 5+ hours saved per week per provider. Plus, Affineon tightly integrates with the EHR, so providers don’t need to change their existing workflow. | $5M / Seed / Feb 03, 2025 | |
Partake Foods
|
Partake Foods is a food and beverage company that specializes in selling allergy-friendly cookies. The company's products are free of the top 12 allergens so families can eat safely, healthfully, and deliciously — even on-the-go. The company was founded in 2016 and is headquartered in Jersey City, New Jersey. | $20.8M / Series B / Oct 04, 2022 | |
Omsom
|
Omsom is a venture-backed CPG brand bringing proud, loud Asian flavors into American homes. It was founded in 2018 and is headquartered in New York. | Seed / Aug 15, 2022 | |
Zero Grocery
|
Zero Grocery provides a convenient zero-waste grocery delivery service. Zero Grocery's mission is to remove single-use plastics from the food system so customers will receive groceries in reusable containers. | Seed / Nov 29, 2021 | |
Ox
|
Ox is an enterprise software provider that develops human-centered automation systems across the supply chain. The Operator Experience directs frontline operators to perform their work through software automation, wearable displays, and artificial intelligence to deliver operational excellence. | $3.5M / Seed / Mar 02, 2021 | |
Madorra
|
Madorra Their goal is empowering women to live fuller, healthier lives. Madorra is working towards changing the paradigm for treating vaginal dryness, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power tochoose the non-hormonal treatment option they want. | Seed / Dec 01, 2020 | |
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Series A / Apr 01, 2020 | |
|
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Series A / Apr 01, 2020 | |
|
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Series B / Apr 01, 2020 | |
Aria CV
|
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart. | $31M / Series B / Feb 25, 2020 | |
| See all 12 investments → | |||
Co-Investors
About Green Park & Golf Ventures
Green Park & Golf, built on over 50 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm iscurrently looking for investment opportunities in medical-related start-ups.Dr. Heighten founded MedicalEdge Healthcare Group in 1993, and Mr. Soderstrom started PhyServe Physician Services in 1998 to administer the financial and operational needs of MedicalEdge. Together, the companies managed over 550 providers in five major markets. In 2011, the companies were sold to Texas Health Resources, a $3.8 billion health care system. That’s when Green Park & Golf was born.After earning his MBA at Southern Methodist University, Mr. Garcia joined them full-time in May 2011 to actively pursue new investment opportunities and monitor other investments in their portfolio. He has prior professional experience at FedEx, Bold Ventures, and Lone Star Investment Advisors.
Green Park & Golf Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
JR Garcia
Principal & VP of Investments
|
|||
Carl Soderstrom
Founding Partner
|
|||
|
Claire England
Investment Partner
|
|||
Clay Heighten
Founding Member
|
|||
|
Dan Parsley
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Claire England invest in?
Claire England invests primarily in Health Care, Wellness and Medical Device startups, most often at Seed and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Claire England last invest?
The most recent investment recorded for Claire England closed in Feb 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
